Policy reform: Strengthen and stabilize the FDA.

Carpenter, Daniel

Carpenter, Daniel.

Affiliation

Carpenter D; Harvard University, Cambridge, Massachusetts 02138, USA. dcarpenter@gov.harvard.edu

Nature ; 485(7397): 169-70, 2012 May 09.

Article in En | MEDLINE | ID: mdl-22575942

Subject(s)

Drug Approval/legislation & jurisprudence; United States Food and Drug Administration/legislation & jurisprudence; United States Food and Drug Administration/organization & administration; Amines/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Bevacizumab; Diet Fads/adverse effects; Dietary Supplements/adverse effects; Dietary Supplements/economics; Dietary Supplements/standards; Disclosure; Drug Approval/economics; Drug-Related Side Effects and Adverse Reactions; Federal Government; Humans; Public Health; Time Factors; Treatment Failure; United States; United States Dept. of Health and Human Services/legislation & jurisprudence; United States Food and Drug Administration/economics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Drug Approval Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Nature Year: 2012 Document type: Article

Fulltext

XML

PubMed Links

Search on Google